Entries of Niederwieser, D on the publication server
 | Up a level |
Number of items: 6.
2014
Ruutu, T, Gratwohl, A, de Witte, T, Afanasyev, B 
, Apperley, J, Bacigalupo, A, Dazzi, F , Dreger, P, Duarte, R, Finke, J, Garderet, L, Greinix, H, Holler, E, Kröger, N, Lawitschka, A, Mohty, M, Nagler, A, Passweg, J, Ringdén, O, Socié, G, Sierra, J, Sureda, A, Wiktor-Jedrzejczak, W, Madrigal, A and Niederwieser, D
(2014)
Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice.
Bone Marrow Transplantation 49 (2), pp. 168-173.
Fulltext not available.
, Apperley, J, Bacigalupo, A, Dazzi, F , Dreger, P, Duarte, R, Finke, J, Garderet, L, Greinix, H, Holler, E, Kröger, N, Lawitschka, A, Mohty, M, Nagler, A, Passweg, J, Ringdén, O, Socié, G, Sierra, J, Sureda, A, Wiktor-Jedrzejczak, W, Madrigal, A and Niederwieser, D
(2014)
Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice.
Bone Marrow Transplantation 49 (2), pp. 168-173.
Fulltext not available.
Koenigsmann, M, Casper, J, Kahl, C, Basara, N, Sayer, H G, Behre, G, Theurich, S, Christopeit, M , Mohren, M, Reichle, A, Metzner, B, Ganser, A, Stadler, M, Uharek, L, Balleisen, L, Hinke, A, Hinke, R and Niederwieser, D
(2014)
Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.
Bone Marrow Transplantation 49 (3), pp. 410-415.
Fulltext not available.
, Mohren, M, Reichle, A, Metzner, B, Ganser, A, Stadler, M, Uharek, L, Balleisen, L, Hinke, A, Hinke, R and Niederwieser, D
(2014)
Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.
Bone Marrow Transplantation 49 (3), pp. 410-415.
Fulltext not available.
2007
Knop, S, Hebart, H, Gratwohl, A, Kliem, C, Faul, C, Holler, E, Apperley, J, Kolb, H J, Schaefer, A, Niederwieser, D and Einsele, H
(2007)
Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party.
Leukemia 21 (8), pp. 1830-1833.
Fulltext not available.
2005
Knop, S, Hebart, H, Gscheidle, H, Holler, E, Kolb, H-J, Niederwieser, D and Einsele, H
(2005)
OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease.
Bone Marrow Transplantation 36 (9), pp. 831-837.
Fulltext not available.
Ruutu, T, Corradini, P , Gratwohl, A, Holler, E, Apperley, J, Dini, G, Rocha, V, Schmitz, N, Socié, G and Niederwieser, D
(2005)
Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT).
Bone Marrow Transplantation 35 (2), pp. 121-124.
Fulltext not available.
, Gratwohl, A, Holler, E, Apperley, J, Dini, G, Rocha, V, Schmitz, N, Socié, G and Niederwieser, D
(2005)
Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT).
Bone Marrow Transplantation 35 (2), pp. 121-124.
Fulltext not available.
2003
Hegenbart, U, Niederwieser, D, Forman, S, Holler, E, Leiblein, S, Johnston, L, Pönisch, W, Epner, E, Witherspoon, R, Blume, K and Storb, R
(2003)
Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria.
Biology of Blood and Marrow Transplantation 9 (11), pp. 689-697.
Fulltext not available.